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Abstract
Cervical cancer (CC) is a very frequent women disease with high mortality and morbid-
ity incidence worldwide, being the developing countries the most affected. Persistent 
infection with an oncogenic high-risk human papillomavirus (HPV) type is the primary 
cause of cervical cancer, but other etiologies are needed for complete malignancy such as 
patient immune response, genetic, and cellular factors, and/or environment. Radiotherapy 
in combination with cisplatinum is the standard treatment for invasive cervical cancer. 
Nevertheless, this conventional treatment is restricted due to eventual development of 
drug resistance and systemic toxicity. MicroRNAs (miRNAs) are small non-coding RNAs 
that regulate the expression of protein-coding genes involved in various cellular pro-
cesses including cancer where they play a very important role in the development and 
progression of malignancy. As part of this complex disease, miRNAs have been impli-
cated in the process of drug and radiation resistance and sensitivity. Recent studies have 
been directed to understand how miRNAs under or over-expressed are determinants 
of clinical response, and other studies have focused to clarify how the process of radio 
and/or chemotherapy affects miRNA expression. These works could lead to the design 
of safer and more effective therapy approaches based on miRNA expression and their 
target regulation.
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1. Introduction
Cervical cancer (CC) is the third most common malignancy disease worldwide and has the 
second place in underdeveloped countries [1]. Persistent infection with an oncogenic  high-risk 
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Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
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human papillomavirus (HPV) is the primary cause of cervical cancer [2], being HR-HPV types 
16 and 18 responsible of 95% of cases. However, additional etiologies are needed for complete 
malignancy to be achieved such as patient immune response, genetic, environmental and/
or socioeconomical factors [3, 4]. HPV persistent cell infection could give the opportunity 
to HPV genome integration [5], which commonly results in viral E2 regulator loss leading 
to E6 and E7 viral proteins constitutive expression allowing development of dysplasia and 
malignity [6]. Importantly, HPV integration is frequently found near microRNAs (miRNAs), 
a type of non-coding RNA genes involved in coding genes post-transcription silencing [7], 
affecting miRNA expression [8]. Aberrant miRNAs expression has been documented for car-
cinogenesis development in cervical cancer and several other cancer types [9]. Additionally, 
miRNA processing machinery misregulation is implicated in carcinogenesis, suggesting that 
they regulate fundamental processes in cancer progression [10].
Concurrent cisplatin-based chemotherapy added to radiation therapy is the standard treatment 
for advanced CC. It has been demonstrated that chemotherapy and radiotherapy improve sur-
vival rates compared to therapy based on radiation alone or combined hysterectomy and radia-
tion. Although a good response to conventional treatment is achieved by some patients, several 
global meta-analyses in developed and developing countries have shown that CC patients 
receiving radiotherapy alone or in combination with different chemotherapeutic agents have 
at 5 years an overall survival rate from 40 to 70% [11–14]. Additionally, systemic toxicity and 
side effects are a major problem that patients present during treatment [15]. Therefore, much 
effort is being made in developing safer and more effective treatment alternatives like natural 
compounds adjuvants [16–18]. Cisplatin and radiation mechanism of action include damage to 
DNA and induction of DNA damage response (DDR) that consists of the action of a plethora 
of genes involved in DNA damage repair. The DDR constitutes the action of detectors of DNA 
damage, signal transducers and effectors that upon effective action of the DDR proteins the 
cell will be lead either to survival or apoptosis mechanisms depending on DNA damage sever-
ity [19–23]. MiRNAs are active modulators of the DDR mechanisms and have been shown 
as promoters or inhibitors of radio- and chemosensitivity [24–28]. Additionally, the miRNA 
response to natural compounds has also been evaluated with respect to treatment resistance 
and sensitivity [29, 30]. Thus, miRNAs have a clear participation in chemo and radio resistance 
and sensitivity implying a high potential in gene therapy, prognosis and diagnosis.
2. Cervical cancer etiology
The human papillomavirus (HPV) infection is a common sexual transmission infection asso-
ciated with cervical intraepithelial neoplasia (CIN) 1, 2, 3, and cervical cancer. More than 
80% of women are infected during their life while a just a minority develops malignancy 
disease [31]. Even though HPV elimination is spontaneous, its persistent cell infection could 
give the opportunity to HPV genome integration [5] allowing development of dysplasia and 
malignity [6]. HPV infects mucosa and cutaneous surfaces via cell membrane heparan sul-
fate proteoglycan [32]. HPV replication is exclusive of the squamous stratified epithelium 
like epidermis or mucosa membranes of cervix [33]. The genes of HPV are classified in early 
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(E1, E2, E4, E5, E6, and E7) and late (L1 and L2). The formers are implicated in viral genome 
replication and transcription, while the latest ones constitute structural virus proteins [34].
Viral genome transcription is dependent on cellular differentiation, specific proteins and 
RNA profile [35, 36]. Upon HPV infection, viral proteins modify normal cell processes. E4 is 
related to the delivery of HPV copies from the cell, while E5 is allied in apoptosis resistance 
[37]. Interaction of E6 with p53 via E6-BP conduces to p53-null phenotype [33, 38] disturbing 
cell cycle and death [39]. On the other hand, E7 interacts with several proteins to boost G1 
to S transition [40–42] permitting cell proliferation, enhancing cancer features [43]. The main 
cell circuit affected by E7 expression is E2F-Retinoblastoma (E2F-Rb). This oncoprotein binds 
to Rb liberating E2F transcription factor, promoting the transcription of C-MYC, DNA poly-
merases, cyclins and CdKs among others [40]. During HPV infection, E2 represses E6 and E7 
permitting cell proliferation and differentiation recover. However, in most cervical tumors, 
E2 is lost during the viral genome integration in the cellular genome allowing, E6 and E7 con-
stitutive expression [6]. It is important to mention that HPV integration is frequently found 
near miRNA genes [7] affecting miRNA expression [8] and probably some other non-coding 
RNAs. As it will be mentioned later on, non-coding RNAs, especially micro-RNAs (miRNAs), 
are important genes in which misregulation is closely linked to cancer development, and 
therefore, HPV integration is crucial for cervical cancer development [8].
3. MicroRNAs in cervical cancer
MicroRNAs are small non-coding genes that exert their function by silencing of coding genes 
in almost every cellular process, like, cell proliferation, apoptosis, differentiation, migration, 
invasion, immune response, and metabolism. Before MiRNAs maturation, pri-miRNAs and 
pre-miRNAs are sequentially spliced by Drosha and Dicer proteins, respectively, generating a 
mature 22–24 nucleotides (nt)-long double strand. To perform mRNA silence mature, miRNAs 
are incorporated into risk silencing complex, and one miRNA strand is lead to base pair to 
target mRNA [44]. Then, mRNA is degraded after perfect hybridization is achieved or pro-
tein translation is inhibited in incomplete base pair hybridization. Aberrant miRNAs expres-
sion has been documented for several carcinomas such as breast, cervical, lung, kidney and 
colon carcinomas among many others [9], and it has been evaluated by microarray, sequenc-
ing, northern blotting, cloning, and reverse transcription-polymerase chain reaction (RT-PCR) 
techniques [45, 46]. Pioneer study relating miRNAs and cervical cancer was made in 2007. In 
this chapter, they sequenced 166 miRNAs comparing normal tissue, cell lines and tumor tis-
sues, founding six miRNAs with differential expressions. MiR-21 was over-expressed in cell 
lines and tumor tissue compared with normal tissue, while let-7b, let7-c, miR-23b, miR-143, 
and miR-196b expressions were reduced [47]. Since then, many studies have addressed the 
importance of microRNAs in cervical cancer. Confirmation of various works has provided very 
useful miRNA expression information to study more profoundly the function and application 
of this miRNAs in cancer therapy, prognosis, and diagnosis. For example, miR-218 has been 
found down-regulated in cervical cancer tissue, and its low expression has been related to 
cancer progression, while its up-regulation in Hela cells has shown that it improves cisplatin 
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sensitivity [48–51]. In silico and in vitro studies have shown that miRNAs can potentially regu-
late more than 100 genes, suggesting a great potential for coding genes regulation in cancer 
cells [52].
4. Cervical cancer therapy
Concurrent cisplatin-based chemotherapy added to radiation therapy is the standard treat-
ment for locally advanced CC (LACC). It has been demonstrated that chemotherapy and 
radiotherapy improve survival rates compared to therapy based on radiation alone or com-
bined hysterectomy and radiation. In addition, randomized trials demonstrated improved 
treatment outcome with combinations of cisplatin and 5-fluorouracil compared with radiation 
therapy alone. It is established that concurrent chemotherapy increases the severity of acute 
side effects; however, it does not appear to increase the risk of late side effects of radiotherapy. 
Although a good response to conventional treatment is achieved by some patients, LACC 
patients treated with radiotherapy have in general a 50% chance of recurrence or persistent 
disease. Moreover, several global meta-analyses, including patients treated in developed and 
developing countries, have shown that CC patients receiving radiotherapy alone or in combi-
nation with different chemotherapeutic agents have at 5 years an overall survival rate from 40 
to 70% [11–13]. This conventional treatment is restricted due to eventual development of drug 
resistance and systemic toxicity; therefore, much effort is being made in developing safer and 
effective alternatives like natural compounds as anti-cancer drugs [16–18].
Other approaches have been made toward developing cisplatin analogues with improved 
chemotherapeutic efficacy and reduced toxic side effects, the most notable of these being car-
boplatin and oxaliplatin clinically registered [53]. Individual trials have suggested that other 
drugs, including mitomycin and epirubicin, might be beneficial [54]. It has been investigated 
the administration of neoadjuvant chemotherapy (NAC), which includes cisplatin, paclitaxel, 
and carboplatin after radiation therapy enhancing the treatment response [55]. Although the 
evidence for benefit of concurrent chemotherapy is strong for newly diagnosed, loco-region-
ally advanced cervical cancers confined to the pelvis, the relative benefits and risks are not 
well understood for patients who require larger fields of radiotherapy [54]. Many studies are 
currently being made to improve CC cancer treatment for a major patient percent recovery 
and less side effects by different approaches as miRNA-based therapy.
5. Cisplatin action mechanism
DNA is vulnerable to damage that originates from endogenous metabolites, such as macro-
phages and neutrophils produced reactive oxygen species (ROS), reactive nitrogen species 
(RNS) [56] and exogenous agents including smoking, chemical carcinogens, radiation [57], 
and genotoxic cancer therapeutics [58]. For instance, cisplatin, cis- diamminedichloroplatinum 
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(II) (NH3)2PtCl2) is a DNA-damaging agent used extensively as a chemotherapeutic drug. 
Particularly, it is successfully employed to treat different cancer types like ovarian and testicu-
lar carcinomas, as well as a range of other solid tumors [59, 60]. However, dose-limiting toxic 
side effects and the occurrence of both acquired and intrinsic drug resistance in cells impose 
great limitations on cisplatin chemotherapy [61–63].
A hallmark of cisplatin toxicity is loss of outer hair-cells (OHCs) beginning from the cochlear 
base. A recent study suggests additionally the involvement of stria vascularis and spiral gan-
glion [64]. One-third of cisplatin-treated cancer patients develop irreversible hearing loss [15]. 
It has been demonstrated that the toxic side effects of cisplatin depend on the drug cell trans-
portation via the copper transporter CTR1, previously implicated in cisplatin-induced neph-
rotoxicity [65, 66] or the organic cation transporter OCT2. Upon partial solvolization, cisplatin 
forms [(NH
3
)
2
PtCl(H
2
O)] + (monoaqua complex), which can be transported by OC.
Although cisplatin detailed mechanism of action is presently unclear, it is generally thought 
that the covalent binding of cisplatin to cellular DNA and subsequent formation of bulky 
platinum-DNA (Pt-DNA) adducts mediates the cytotoxicity of this anti-cancer agent [67, 68]. 
Intra-strand DNA cross-links are the most common adducts formed, although inter-strand 
DNA cross-links and DNA-protein cross-links can also occur [69, 70]. The intra-strand DNA 
lesions preferentially form between the N-7 of adjacent guanine residues, inhibiting the pas-
sage of polymerases and thus interfering with DNA replication and RNA transcription inside 
target cells [71–74].
The active response to cisplatin induces DNA damage entailing two key processes. (1) Repair 
of DNA damage through the removal of cisplatin adducts and (2) induction of cell death via 
apoptosis when repair cannot be carried out successfully. Among these DNA repair path-
ways, NER repairs damaged DNA commonly caused by chemotherapeutics such as platinum 
drugs, which has been proven to be associated with chemotherapy resistance in non-small cell 
lung cancer (NSCLC) [19].
Cisplatin’s mechanism of action in addition to cell cycle arrest and apoptosis includes cellular 
senescence through activation of onco-suppressing p53 and p16 proteins, and there is strong 
evidence that p53 plays a role in cisplatin sensitivity [75]. Transcription factor NFκB and the 
serine/threonine kinase Akt play critical roles in cancer cell survival and have been shown 
to be activated in various malignancies [76]. Thus, efforts are underway to identify alternate 
therapies, including the use of curcumin in combination with radiation and/or chemothera-
peutic drugs in hepatic, ovarian, and head and neck squamous cell cancer HNSCC [77–79]. 
It is believed that the therapeutic potential of cisplatin will be enhanced with the addition of 
curcumin, with lower, less toxic doses of cisplatin required for its cytotoxic effect [30].
6. Ionizing radiation action mechanism
Ionizing radiation is a type of high-energy radiation that in contact with atoms and molecules 
releases electrons generating ions that can break covalent bonds. Ionizing radiation directly 
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affects DNA structure by inducing DNA breaks, particularly double-strand breaks (DSBs). 
Secondary effects are the generation of reactive oxygen species (ROS) that oxidize proteins 
and lipids and induce several damages to DNA like generation of a basic sites and single-
strand breaks (SSBs). Quiescent and slowly dividing cells are less radiosensitive, like those 
constituting the nervous system, while cells with high proliferation rates are more radiosensi-
tive, like bone marrow, skin, and epithelial cells of the gastro-intestinal tract, among others. 
Ionizing radiation can be divided into X-rays, gamma rays, alpha, and beta particles, and neu-
trons. The radiation dose is measured in gray (Gy) units, a measure of the amount of radiation 
absorbed by 1 kg of tissue [20].
Radiotherapy is a treatment aimed at shrinking the tumor mass or at eliminating residual 
tumor cells by exposing the tumor to ionizing radiation. Radiotherapy regimes mostly use 
X- and gamma radiation and affect tumor and healthy irradiated cells indistinctly [80].
Ionizing radiation causes DSBs directly, and reactive oxygen species (ROS) caused by radia-
tion also indirectly damages DNA. ROS generate apurinic/apyrimidinic (abasic) sites in the 
DNA, SSBs, sugar moiety modifications, and deaminated adducted bases [81, 82]. After DNA 
damage, the cell repair machinery is activated and stops the cell cycle at specific control 
checkpoints to prevent continuation of the cycle and repair damaged DNA. If tumor cells 
can efficiently repair the radiation damage, resistance to radiation develops, enabling cells 
to survive and replicate. If the damage remains unrepaired, these mechanisms induce pro-
grammed cell death or apoptosis to prevent accumulation of mutations in daughter cells 
[83, 84]. Ionizing radiation unavoidably spreads to normal tissue, inducing side effects in 
tumor-adjacent normal cells that may contribute to chromosomal aberrations and to increase 
the risk for new malignancies. Therefore, reduced patients survival could be a consequence 
of high radiation doses administation [21].
Individual radiation treatment based on DSB repair capability could predict toxicity to sur-
rounding tissues, thereby improving treatment safety. DSB repair capability depends not just 
on gene integrity, but also on gene expression. For example, genetic and epigenetic mecha-
nisms may reduce or abrogate the expression of genes involved in DSB repair [85]. DNA 
repair is orchestrated by a series of pathways, mainly including nucleotide excision repair 
(NER), base excision repair (BER), DNA mismatch repair (MMR), and single-strand break 
repair (SSBs) [86]. DSB repair is achieved in three ways: non-homologous end joining (NHEJ), 
conservative homologous recombination (HR), and single-strand alignment (SSA), also called 
non-conservative homologous recombination [87].
Three interconnected sensor systems have been described that have the ability to detect a single 
DSB within minutes after its formation [88]: (1) PI3K-related kinases (PIKKs), (2) ataxia telangi-
ectasia and Rad3-related (ATR), ataxia telangiectasia mutated (ATM) and (3)  DNA-dependent 
protein kinase (DNA-PK). ATR participates in the recognition of SSBs induced by cisplatin 
or IR, whereas ATM is essentially implicated DSBs recognition. Importantly, damage sig-
nals are transduced to the cell, while cells react to decide to either repair damaged DNA or 
activate cell cycle checkpoints or induce apoptosis. Upon DSBs induced by cisplatin and/
or radiation, as a transducer, the targets of ATM/ATR with dual-functions promote sur-
vival or cell death. Meanwhile, cell signaling pathways activate cell cycle checkpoint halting 
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its  progression  proving time to cells to repair the damage by the recruitment of DNA repair 
proteins to facilitate DSB repair triggered by NHEJ or HR, depending on the cell cycle phase 
[22]. If DNA damage is greater than the repair capacity, hence replication and transcription 
will be blocked, and DDR signals activate downstream cell death pathways. Importantly, 
DNA repair genes are actively regulated by miRNAs, which are highly found misregulated 
in cervical cancer and have marked effect on chemo- and radiotherapy resistance, implying a 
big target potential in gene therapy.
7. MiRNAs in mechanisms of cancer therapy resistance
Some studies have enlightened miRNAs contribution to chemo- and radiotherapy response; 
for example, it was shown that cisplatin, paclitaxel, and carboplatin prior to laparoscopic 
radical hysterectomy (LRH) improved patient response by inducing p53, miR-34a, and 
 miR-605 expression, while levels of E2F1 and Mdm2 were significantly low [55]. Additionally, 
alternative less toxic natural compounds are analyzed; for example, it was shown that I´5-
I´acetoxichavicol acetate (ACA) induced comparable levels of dose- and time-dependent cyto-
toxicity on a variety of tumor cell lines to current commercial anticancer drugs, without any 
adverse effects on normal cells [29]. A total of 25 miRNAs were found to be expressed sig-
nificantly different in response to ACA and/or cisplatin including has-miR-138, has-miR-210, 
has-miR-744 which target genes involved in apoptosis and cell cycle progression regulating 
pathways [89].
Genotoxic agents, such as UV light, γ-irradiation, oxidative stress, and chemical mutagens, 
induce a DDR that results in the up- and down-regulation of miRNAs expression levels that 
will happen in a few hours after DNA damage and will return to basal levels in 24 h. MiRNA 
DDR seems to be influenced by type of damaging agent, radiation Gy dose and time of expo-
sure as well as cell type involved [90–94]. MiRNA-induced response has been documented 
as transcriptionally modulated miRNA expression and biogenesis modulation miRNA 
maturation.
In response to DNA damage, the ATM or ATR kinase activates p53, which in turn transacti-
vates genes involved in cell cycle regulation, senescence, and apoptosis. A clear example is 
the transactivation of miRNA-34 family by p53 upon DNA damage and oncogenic stress [95]. 
MiR-34a ectopic expression leads to G1 phase cell cycle arrest in both primary and tumor-
derived cell lines likely through silencing a program of genes that promote cell cycle progres-
sion. In addition to the miR-34 family, miR-192, miR-194, miR-215, and miR-17-92 cluster 
are other miRNAs found to be transcriptionally regulated by p53. In addition, other DNA 
damage responsive transcription factors, such as NF-κB, c-Myc, CREB and E2F1, modulate 
miRNA expression [96, 97]. However, the specific functions of those miRNAs in DNA dam-
age need further study.
MiRNAs involvement in DDR seems to be additionally modulated beyond transcription reg-
ulation by transcription factors through post-transcription modulation. Miyazono group´s 
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study demonstrated that several miRNAs, including miR-16-1, miR-143 and miR-145, were 
post-transcriptionally up-regulated in a p53-dependent and p68/p72-dependent manner 
upon genotoxic stress [98, 99]. In colorectal HCT116 and lung WI-38 cell lines, p53 interacts 
with the Drosha processing complex through direct interaction with p68 and, in turn, facili-
tates the processing of primiRNAs to pre-miRNAs. Apparently, the guardians of genome, 
p53/p63/p73, modulate the processing of a group of miRNAs, including the tumor suppressor 
miRNAs, let-7, miR-34, miR-15/16a, miR-145, miR-26, miR-29, and miR-146a [100]. Another 
protein modulating miRNA processing is KSRP, a KH type splicing ribonucleoprotein that 
serves as a critical component of both Drosha and Dicer complexes and regulates the bio-
genesis of a subset of miRNAs like miR-16 and miR-143 and miR-145 by Drosha and Dicer 
respectively [101].
As a response to DNA damage, a novel class of small RNAs, named DDR-regulating RNAs 
(DDRNAs), has been identified near double-strand breaks (DSB) [102]. It has also been 
reported the presence of Dicer-dependent small RNAs (named DSB-induced RNAs, diRNAs) 
arising from the sequences flanking DSBs in plants and in human cells [103]. At the moment 
how do these site-specific small RNAs act to control DDR activation, it is not clear; however, it 
seems that the presence of DSB-derived site-specific small RNAs may be a universal phenom-
enon in DNA damage, involved in recruitment of chromatin-modifying complexes to sites of 
damage or guiding DNA repair signaling [104].
MiRNAs are also involved in mechanisms of multidrug resistance (MDR) like dysregulation of 
drugs transporters, defects of apoptosis and autophagy machinery, alterations of drug metab-
olism and drug targets, and disruption of redox homeostasis [28]. Some miRNAs regulating 
drug transporters like (P-gp/ABCB)1 are miR-451, miR-27a [105–108], miR-138 [109], miR-298 
[110], miR-381, and miR-495 [111]. The entire process of autophagy, including autophagic 
induction, vesicle nucleation, vesicle elongation, and completion, can be modulated by dif-
ferent miRNAs [28]. Some miRNAs documented in this cellular process are miR-30a [112], 
miR-30d [113], miR-204 [114], miR-16 and miR-17 [115, 116], miR-200b, miR-15a [116], and 
miR-181a [117]. Metabolic regulation by miRNAs has been documented for miR-27b, which 
can modulate resistance to docetaxel in cancerous cells [118, 119] and sensitizes cancer cells to 
a broad spectrum of anti-cancer drugs in vitro and in vivo by activating P53-dependent apop-
tosis and reducing CYP1B1-mediated drug detoxification [120], and for miR-892a that targets 
CYP1A1 [121]. Apparently, miRNAs can impact anti-cancer drugs sensitivity by modulating 
the expression of drug targets. For example, miR-192 and miR-215 may influence 5-FU sen-
sitivity by targeting Tynidilate synthetase (TS) enzyme in colorectal cancer cells [122], while 
miR-211 can increase the sensitivity of pancreatic cancer cells to gemcitabine [123], and let-7 
negatively regulates RRM2 expression and sensitizes PDAC cells to gemcitabine [28].
8. MicroRNAs in cervical cancer chemo- and radiotherapy resistance
Additionally to several works involving coding genes, other efforts involving miRNAs are 
being made for the understanding of cellular chemo- and radiosensitivity. In this context, it 
Colposcopy and Cervical Pathology92
has been shown that miRNAs expression is affected in radio and chemo-resistant cells [25–28]. 
Some miRNAs have been identified as promoters of radioresistance such as miR-421, which 
regulates the activity of DNA repair ATM protein [124]; miR-23b and miR-34a, which are 
regulated by p53 protein [125]; miR-106b, which silences cell cycle regulator protein p21 and 
promotes cell cycle progression and overrides a doxorubicin-induced DNA damage check-
point and miR-17-92 cluster [126, 127]; while others have been found as radiosensitizers such 
as miR-424 promoting radiosensitivity by targeting aprataxin, which stimulates DNA repair 
and protects cells against genotoxic stress in cancer cells [128] and miR-375 promoting radio-
sensitivity of HR-HPV-positive cervical cancer cells by targeting the ubiquitin ligase mRNA 
(UBE3A) leading to decreased p53 degradation and thereby increasing radiation-induced 
apoptosis [129]. Interestingly, miR-375 was also found increased in acquired paclitaxel resis-
tance in cervical cancer [130].
Some studies have shown that miRNAs involved in chemosensitivy promotion. For instance, the 
sensitivity to cisplatin is augmented via miR-181a Protein Kinase C Delta (PRKCD) silencing [131] 
and miR-218, which also impairs tumor growth and induces apoptosis via AKT-mTOR pathway 
in HeLa cells [50]. Additionally, miR-218 enhances Rapamacyn sensitivity by mTor pathway 
Rictor targeting [132]. An study showed that p53:miR-34a:E2F1 and p53:miR-605:Mdm2 are acti-
vated after chemotherapy with cisplatin, paclitaxel, and carboplatin cycles improving the treat-
ment response of cervical cancer patients [55]. Other cisplatin sensitizing miRNAs are miR-15b 
and miR-16 that target Bcl2 in Hela cells [133], while miR-15a and miR-16 induce autophagy and 
sensitize cells to camptothecin [116]. Other miRNAs promote chemosensitivity to other drugs, 
for example, miR-126 additionally to hinder proliferation it enhances sensitivity to bleomycin 
[134]; mir-125a, promotes paclitaxel sensitivity via silencing of signal transducer and activator of 
transcription (STAT3) [135], and miR-145 that is regulated by p53 influences sensitivity to mito-
mycin and reverses the chemoresistance induced by glucocorticoids [136].
Recent works have focused on the design of radio and chemotherapy response predictors. 
Pedroza-Torres and cols identified a miRNA expression signature based on the over-expres-
sion of seven miRNAs (miR-31-3p, miR-3676, miR-125a-5p, miR-100-5p, miR-125b-5p, miR-
200a-5p, and miR-342) to identify CC patients who could fail to conventional, treatment 
based on chemo- and radiotherapy [137]. Other works have provided similar valuable 
information, for example, miR-200a and miR-9 signature could predict patient survival. 
Particularly, miR-200a could affect the metastatic potential of cancer cells by negatively 
regulating cell motility genes [138]. Another study indicated that the miRNA signature con-
sisting of miR-630, miR-1246, miR-1290, and miR-3138 could promote radio resistance of CC 
cells [138–140].
A total of 25 miRNAs were found to be differentially expressed in response to 1S-1-
acetoxychavicol acetate (ACA) and/or cisplatin. MiR-138, miR-210, and miR-744 have predicted 
gene targets involved in signaling pathways regulating apoptosis and cell cycle progression. 
Remarkable, ACA acts as a chemosensitizer that synergistically potentiates the cytotoxic 
effect of cisplatin in cervical cancer cells. MiRNA expression changes with the administra-
tion of ACA and/or cisplatin suggests that miRNAs play an important role in anticancer drug 
responses making them ideal for therapeutic treatment of patients with chemoresistance [89].
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Curcumin (Cur) is a phenolic compound purified from the rhizome of Curcuma longa, 
historically used in traditional medicine [141, 142]. It has been reported that Cur reduces 
the expression and function of P-glycoprotein (P-gp), a protein highly expressed in 
tumoral cells [143]. This natural compound and derivatives have been catalogued as not 
toxic in humans even at high doses (12 g/day) [144]. Cur efficacy is limited due to the low 
level of oral bioavailability, poor absorption ability, a high metabolic rate, inactivity of 
metabolic products, rapid elimination and clearance from the body, poor pharmacokinet-
ics and solubility, and degradation under natural to basic pH conditions. Conjugation 
of Cur to nanoparticles (NPs) and anti-P-glycoprotein (P-gp) antibody (Cur-NPs-APgp) 
targeting to P-gp could enhance paclitaxel (PTX) sensitivity both in vitro and in vivo 
[140]. Curcumin reverses cisplatin resistance in SiHa-resistant phenotype (SiHaR) cells by 
overcoming over-expression of multidrug resistance protein 1 (MRP1) and Pgp1 and sen-
sitized cervical cancer cells toward cisplatin-induced cell killing with lower chemothera-
peutic drug dose [145]. Recent evidence has suggested curcumin-induced modulation of 
the expression of several miRNAs such as suppression of oncomiRs miR-21, miR-17-5p, 
miR-20a, and miR-27a and over-expression of miR-34 a/c and epithelial-mesenchymal 
transition-suppressor miRNAs among the most important effects of curcumin on miRNA 
homeostasis [24].
Other natural compounds with anticancer potential are Cratoxylum formosum subsp. pruni-
florum (Kurz.) Gogel. (Teawdang) phenolic extracts that could inhibit growth of HeLa and 
Siha cancer cell lines [146]. Teawdang is a northeast Thai vegetable that contains several bio-
active constituents especially chlorogenic acid which has radical scavenging activity [147]. 
Thus, miRNA regulation investigation of these bioactive compounds is recommended. It 
could be very supportive the study of miRNA response to other natural compounds with 
anticancer potential and drug resistance overcome like Chrysin from Thai propolis [148]; a 
series of ferrocene and (arene)ruthenium(II) complexes attached to the naturally occurring 
anticancer naphthoquinones plumbagin and juglone [149]; sesquiterpene lactones isolated 
from Illicium simonsii [150]; phenanthroindolizidine alkaloids, (−)-(R)-13aalpha-antofine 
(1) and (−)-(R)-13aalpha-6-O-desmethylantofine (2) and natural products, (−)-(R)-13a alpha-
secoantofine (3) and (−)-(R)-13a alpha-6-O-desmethylsecoantofine isolated from Cynanchum 
vincetoxicum [151].
9. Conclusions and considerations
In the present literature, it is reviewed, analyzed, and organized novel information regard-
ing miRNAs involved in resistance to drugs, natural compounds and radiation in cervical 
cancer treatment. The present data could encourage future research to generate optimal 
treatment strategies for individual patients especially before the course of chemo- and 
radiotherapy based on miRNAs regulation, conventional and non-conventional cervical 
cancer therapy.
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